José Rafael P. Zuzuárregui

José Rafael P. Zuzuárregui

Auto-generated profile, based on publicly available information

José Rafael P. Zuzuárregui

Parkinson’s Disease, Research, Education and Clinical Center, San Francisco Veterans Affairs Health Care System, CA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2020 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
JZJosé Rafael P. Zuzuárregui
José Rafael P. Zuzuárregui
EDEmmanuel H. During
Emmanuel H. During

3 April 2020 in Journal of Parkinson’s Disease
Verified
Journal Article
Open access
PDF file
JZJosé Rafael P Zuzuárregui
José Rafael P Zuzuárregui
JOJill L Ostrem
Jill L Ostrem
Background: Parkinson’s disease (PD) can have a significant impact on sleep. Deep brain stimulation (DBS) is an effective treatment for motor features of PD, but less is understood about the impact DBS may have on sleep architecture and various sleep

24 February 2021 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
LPLinda H. Poon
Linda H. Poon
ALAudrey J Lee
Audrey J Lee
MVMai Vuong
Mai Vuong
JZJose Rafael Zuzuarregui
Jose Rafael Zuzuarregui
Purpose: Amantadine is commonly used to treat Parkinson’s disease. A case of myoclonus and asterixis was associated with amantadine is reported. Case Summary: An 80-year-old man with Parkinson’s disease diagnosed in 2015 was started on amantadine for treatment of progressive tremor and orofacial dyskinesias induced by levodopa. He took amantadine 100mg orally daily for 7 days, then increased to 100mg twice a day thereafter. The patient complained of “worsening tremor” after 9 days and amantadine was decreased to 100mg daily. After 1 month on this dose, the patient reported that his “tremor” persisted and experienced visual hallucinations. His examination demonstrated diffuse myoclonus throughout his extremities and trunk, as well as asterixis when attempting to stand or holding his arms antigravity. Laboratory testing for renal and hepatic failure was unrevealing. Amantadine was reduced to 50mg daily for 4 days and then discontinued. Myoclonus resolved 3 days after discontinuation of amantadine. Conclusion: While amantadine-induced myoclonus is rare, health care providers should be vigilant in monitoring for signs and symptoms of myoclonus following amantadine initiation.

1 August 2020 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
JZJosé Rafael P. Zuzuárregui
José Rafael P. Zuzuárregui
IBIan O. Bledsoe
Ian O. Bledsoe
EBEthan G. Brown
Ethan G. Brown
CDCameron G. Dietiker
Cameron G. Dietiker
NGNicholas B. Galifianakis
Nicholas B. Galifianakis

17 October 2025 in Journal of Occupational and Environmental Medicine
Verified
Journal Article
Closed access
Linda ChaoLinda Chao
Linda Chao
TSTamara Sabrina Stiep
Tamara Sabrina Stiep
JZJosé Rafael P. Zuzuárregui
José Rafael P. Zuzuárregui
Objective: To assess deployed Gulf War (GW) veterans for prodromal Parkinson's Disease (PD) using the REM Sleep Behavioral Disorder (RBD) Screening Questionnaire (RBDSQ). Methods: GW veterans ( n = 165) were assessed for nonmotor PD symptoms with the RBDSQ, Non-Motor Symptoms Scale, and Scales for Outcomes in Parkinson's Disease–Autonomic. Some veterans were also assessed with the University of Pennsylvania Smell Identification Test ( n = 120), neurological examinations ( n = 41), and 3T magnetic resonance imaging ( n = 16). Results: Eighty percent of veterans with PD and 73% of veterans without PD had probable RBD (ie, RBDSQ ≥5). Exploratory analysis conducted for hypothesis-generating purposes revealed that RBDSQ scores were positively associated with GW deployment–related exposures and inversely associated with brainstem volume. Conclusions: These findings suggest that veterans with GWI and high levels of deployment-related exposures are at risk for prodromal PD, possibly through RBD as a mediator.